Details for New Drug Application (NDA): 216165
✉ Email this page to a colleague
The generic ingredient in EXBLIFEP is cefepime hydrochloride; enmetazobactam. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cefepime hydrochloride; enmetazobactam profile page.
Summary for 216165
Tradename: | EXBLIFEP |
Applicant: | Allecra Theraps |
Ingredient: | cefepime hydrochloride; enmetazobactam |
Patents: | 0 |
Suppliers and Packaging for NDA: 216165
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165 | NDA | Allecra Therapeutics SAS | 83289-101 | 83289-101-02 | 10 VIAL, SINGLE-DOSE in 1 CARTON (83289-101-02) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 2GM BASE/VIAL;0.5GM/VIAL | ||||
Approval Date: | Feb 22, 2024 | TE: | RLD: | Yes |
Complete Access Available with Subscription